
    
      This is a Phase 3 randomized, placebo-controlled, double-blind, multi-center trial stratified
      by donor age and by region to evaluate the reduction in incidence and severity of delayed
      graft function with kidney allografts from DBD donors who were at least 45 years of age.
    
  